The Dow falls more than 150 points after a poor read on job creation in March raises fresh doubts about the pace of the economy's recovery.
Here are today's top research calls.
The purchase of Allos Therapeutics cannot make up for the loss of Spectrum's bladder cancer drug. (Stocks include SPPI, ALTH, GILD)
Partial results from a mid-stage study of hepatitis C drugs from Bristol and Gilead was leaked in advance of a key meeting in two weeks.
These stocks, which go ex-dividend Tuesday, are rated buy at TheStreet Ratings.
These stocks received downgrades by TheStreet Ratings last week.
When the next round is required, I expect the Fed will attempt to drive down loan rates with the least amount of balance-sheet expansion as possible.
The media needs to ask where 'cost savings' come from.
These stocks received upgrades to buy at TheStreet Ratings last week.
A bump in March sales shows Volt is outstripping the competition.